Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome
1 other identifier
interventional
8
1 country
1
Brief Summary
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 5, 2008
CompletedFirst Posted
Study publicly available on registry
May 7, 2008
CompletedMay 7, 2008
May 1, 2008
May 5, 2008
May 6, 2008
Conditions
Keywords
Study Arms (2)
2
PLACEBO COMPARATORsubcutaneous isotonic saline
1
ACTIVE COMPARATORsubcutaneous GLP-2
Interventions
Eligibility Criteria
You may qualify if:
- clinical diagnose of short bowel syndrome 4 month of stable fase
You may not qualify if:
- activity in IBD
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Glostrup University Hospital
Glostrup Municipality, Capital Region, 2600, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 5, 2008
First Posted
May 7, 2008
Last Updated
May 7, 2008
Record last verified: 2008-05